JP2002520282A5 - - Google Patents

Download PDF

Info

Publication number
JP2002520282A5
JP2002520282A5 JP2000558815A JP2000558815A JP2002520282A5 JP 2002520282 A5 JP2002520282 A5 JP 2002520282A5 JP 2000558815 A JP2000558815 A JP 2000558815A JP 2000558815 A JP2000558815 A JP 2000558815A JP 2002520282 A5 JP2002520282 A5 JP 2002520282A5
Authority
JP
Japan
Prior art keywords
composition
hydrogen
group
lower alkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000558815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002520282A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/015501 external-priority patent/WO2000002555A1/en
Publication of JP2002520282A publication Critical patent/JP2002520282A/ja
Publication of JP2002520282A5 publication Critical patent/JP2002520282A5/ja
Pending legal-status Critical Current

Links

JP2000558815A 1998-07-09 1999-07-08 慢性リンパ性白血病の処置のための方法および組成物 Pending JP2002520282A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9246698P 1998-07-09 1998-07-09
US9487898P 1998-07-29 1998-07-29
US60/094,878 1998-07-29
US60/092,466 1998-07-29
PCT/US1999/015501 WO2000002555A1 (en) 1998-07-09 1999-07-08 Methods and compositions for the treatment of chronic lymphocytic leukemia

Publications (2)

Publication Number Publication Date
JP2002520282A JP2002520282A (ja) 2002-07-09
JP2002520282A5 true JP2002520282A5 (enExample) 2006-10-05

Family

ID=26785713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000558815A Pending JP2002520282A (ja) 1998-07-09 1999-07-08 慢性リンパ性白血病の処置のための方法および組成物

Country Status (12)

Country Link
US (3) US6573292B1 (enExample)
EP (1) EP1104297B8 (enExample)
JP (1) JP2002520282A (enExample)
AT (1) ATE315392T1 (enExample)
AU (1) AU767586B2 (enExample)
CA (1) CA2336932A1 (enExample)
DE (1) DE69929440T2 (enExample)
DK (1) DK1104297T3 (enExample)
ES (1) ES2255287T3 (enExample)
NZ (1) NZ509376A (enExample)
PT (1) PT1104297E (enExample)
WO (1) WO2000002555A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520282A (ja) * 1998-07-09 2002-07-09 フランシス エイ． ナーデラ， 慢性リンパ性白血病の処置のための方法および組成物
US7151100B1 (en) 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7361680B2 (en) 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7129262B2 (en) 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
WO2004026116A2 (en) 2002-09-19 2004-04-01 The Regents Of The University Of California Use of etodoclac to treat hyperplasia
TW200526668A (en) * 2003-10-02 2005-08-16 Salmedix Inc Substituted indole derivatives
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
EP1814544A4 (en) * 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
GEP20156300B (en) * 2008-05-20 2015-06-25 Incuron Llc Inducing cell death by inhibiting adaptive heat shock response
CN104224703A (zh) * 2008-09-25 2014-12-24 赛福伦公司 苯达莫司汀的液体配制品
KR20110110293A (ko) * 2009-01-15 2011-10-06 세파론, 인코포레이티드 벤다무스틴 유리 염기의 신규 형태
BR112013003671A2 (pt) 2010-08-18 2017-01-10 Del Mar Pharmaceuticals composições e métodos para melhorar os benefícios terapêuticos de compostos químicos administyrados sub-otimamente incluindo hexitóis substituídos tais como dianidrogalactitol e diacetildianidrogalactiol
CA2863679A1 (en) 2011-08-17 2014-05-30 Dennis Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
CN115778934A (zh) 2012-01-20 2023-03-14 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US9814693B2 (en) 2012-05-09 2017-11-14 Delmar Pharmaceuticals, Inc. Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
JP2017513933A (ja) 2014-04-06 2017-06-01 インクロン， リミテッド ライアビリティー カンパニー クラキシンとの併用療法
JP7054691B2 (ja) 2016-05-04 2022-04-14 インメド ファーマシューティカルズ インコーポレイティド 表皮水疱症及び関連する結合組織疾患の治療におけるカンナビノイドの局所製剤の使用
US12357604B2 (en) 2017-09-22 2025-07-15 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL107185C (enExample) 1957-12-19
US3843480A (en) 1963-08-28 1974-10-22 D Dreher Dry dry transfer
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3948262A (en) 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3939178A (en) 1971-06-01 1976-02-17 American Home Products Corporation Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles
US3974179A (en) 1971-06-01 1976-08-10 American Home Products Corporation 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetamides and derivatives
US3843681A (en) 1971-06-01 1974-10-22 American Home Prod 1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3839178A (en) * 1972-10-05 1974-10-01 Gen Electric Potentiometric oxygen sensor
US4310509A (en) 1979-07-31 1982-01-12 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
JPS5777617A (en) 1980-10-20 1982-05-15 Nichiban Co Ltd Plaster for cardiac disease
IL61721A (en) 1980-12-16 1984-03-30 Blank Izhak Nitroglycerin preparations
US4542013A (en) 1981-07-08 1985-09-17 Key Pharmaceuticals, Inc. Trinitroglycerol sustained release vehicles and preparation therefrom
US4460562A (en) 1982-01-06 1984-07-17 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4485097A (en) 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
US4542012A (en) 1982-07-02 1985-09-17 Minnesota Mining And Manufacturing Company Film-forming composition containing an antimicrobial agent and methods
US4608249A (en) 1982-11-02 1986-08-26 Nitto Electric Industrial Co., Ltd. Hydrophilic therapeutic material
IT1153909B (it) 1982-12-17 1987-01-21 Sogimi Srl Polimeri reattivi per la cura di affezioni cutanee
GB8317576D0 (en) 1983-06-29 1983-08-03 Shaw A S W Consumer tobacco products
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4585877A (en) 1985-05-06 1986-04-29 American Home Products Corporation Process for preparing 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)-indole-1-acetic acid, etodolac
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4686213A (en) * 1986-08-15 1987-08-11 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids
US4748252A (en) 1986-08-15 1988-05-31 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids
WO1993017680A1 (en) 1992-03-13 1993-09-16 Sepracor, Inc. Antipyretic and analgesic methods and compositions containing optically pure r-etodolac
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6160018A (en) 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US5599946A (en) 1995-05-30 1997-02-04 Teva Pharmaceutical Industries Ltd. 3-(2-trialkylsilyloxy)ethyl-7-ethyl-1H-indoles and method for their preparation
AU706089B2 (en) * 1995-07-19 1999-06-10 Merck Frosst Company Method of treating colonic adenomas
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
US6255347B1 (en) 1996-06-21 2001-07-03 Advanced Research And Technology Institute Methods and compositions comprising R-ibuprofen
CN1230948A (zh) * 1996-07-26 1999-10-06 美国家用产品公司 吡喃并吲哚和咔唑cox－2抑制剂
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
EP1920773B1 (en) * 1996-11-05 2011-01-05 The Children's Medical Center Corporation Thalidomide and dexamethasone for the treatment of tumors
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
JP2002520282A (ja) * 1998-07-09 2002-07-09 フランシス エイ． ナーデラ， 慢性リンパ性白血病の処置のための方法および組成物
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
EP1307459A2 (en) 2000-08-09 2003-05-07 The Regents of the University of California Indole compounds useful for the treatment of cancer

Similar Documents

Publication Publication Date Title
US6921772B2 (en) Methods and compositions for the treatment of chronic lymphocytic leukemia
JP2002519425A5 (enExample)
JP2004509061A5 (enExample)
JP2001512103A5 (enExample)
MY125662A (en) Pharmaceutical formulations containing darifenacin
RU2003107921A (ru) Селективные циклопептиды
JP2008511633A5 (enExample)
JP2002510633A5 (enExample)
MY118156A (en) Oral compositions of levosimendan.
EP1189659A4 (en) IMPROVED MEDICAMENT PACKAGING
JP2001526218A5 (enExample)
JP2002543144A5 (enExample)
JP2003534246A5 (enExample)
JP2003502367A5 (enExample)
JP2002522501A5 (enExample)
JP2002506864A5 (enExample)
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
RU2004131214A (ru) Способы лечения когнитивных расстройств
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
JP2001519413A5 (enExample)
JP2002526550A5 (enExample)
CA2376023A1 (en) Therapeutic agents
TW200517127A (en) Novel composition
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
JP2003534318A5 (enExample)